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Introduction
The majority of proteins targeted to lysosomes are destined for
degradation. However a small number of cell types use the
lysosome not only as a degradative organelle but also as a
regulated secretory organelle. In these cell types a number of
secretory proteins are targeted to the lysosomes for release at
the plasma membrane and efficient lysosomal targeting is
important for the secretory activity of these cells.
Fas ligand (FasL) is a Type II transmembrane protein and
a member of the TNF family of proteins expressed by
activated CD4+ and CD8+ cytotoxic T lymphocytes (CTL),
natural killer (NK) cells and a small number of non-lymphoid
cells. Upon recognition of Fas, membrane-bound FasL
triggers rapid apoptosis in the Fas-bearing cell. FasL plays a
key role in regulation within the immune system and loss of
FasL gives rise to autoimmune lymphoproliferative syndrome
(ALPS1B) (Wu et al., 1996). FasL is targeted to the
multivesicular bodies (MVB) of secretory lysosomes
(Andreola et al., 2002; Frangsmyr et al., 2005; Smith et al.,
2003) and has been isolated on secreted bioactive
microvesicles (Jodo et al., 2000; Martinez-Lorenzo et al.,
1999; Mincheva-Nilsson et al., 2000; Monleón et al., 2001)
thought to derive from these inner membrane vesicles. Small
microvesicles are released into the synaptic cleft between
CTL and target (Peters et al., 1989). The release of FasL into
the cleft on microvesicles provides a mechanism by which
FasL is released in its membrane-bound form, which is 1000
times more biologically active than the cleaved soluble form
generated by metalloprotease cleavage of FasL that occurs
upon translocation to the plasma membrane (Kayagaki et al.,
1995; Schneider et al., 1998). Sorting to the inner vesicles of
secretory lysosomes is therefore an important step for optimal
biological activity of FasL.
Studies on epidermal growth factor receptor (EGFR) have
elucidated many of the steps for sorting mammalian
transmembrane proteins into the MVB pathway. The sorting
signal is a mono-ubiquitin modification that can be
recognised by hepatocyte growth factor-regulated receptor
tyrosine kinase substrate (Hrs) and the endosomal sorting
complexes required for transport (ESCRTs) many of which
contain ubiquitin recognition motifs. Recognition by the
ESCRTs mediates the internalisation of EGFR into the
lumenal vesicles of the MVBs and ultimately transport to the
lysosome (Katzmann et al., 2002). Mono-ubiquitylation is
dependent on autophosphorylation of EGFR (Sorkin et al.,
1992), which is required for binding of the ubiquitin ligase,
Cbl (Waterman et al., 2002), and subsequent ubiquitylation
of EGFR (Jiang and Sorkin, 2003). Disruption of the sites of
either phosphorylation or ubiquitylation prevent EGFR from
being internalised into the lumenal vesicles of MVBs.
The mechanisms that regulate sorting of FasL into the inner
vesicles of secretory lysosomes are not understood. In this
paper we show that phosphorylation of FasL by some members
of the Src family tyrosine kinases through binding to the
proline-rich domain (PRD) of FasL and ubiquitylation both
control the internalisation of FasL into MVBs.
Fas ligand (FasL), a potent mediator of apoptosis expressed
by CTL and NK cells, is sorted into the inner vesicles of
secretory lysosomes for release via exosome-like vesicles.
Previous studies identified a proline-rich domain in the
cytoplasmic tail required for sorting FasL to secretory
lysosomes, but the mechanisms by which this occurs have
not been identified. Here we demonstrate that the PRD of
FasL binds Fgr, Fyn and Lyn tyrosine kinases, leading to
phosphorylation of FasL. Loss of phosphorylation reduces
internalisation of FasL into multivesicular bodies. FasL is
also directly mono-ubiquitylated at lysines flanking the
PRD and mutation of these lysines reduces MVB
localisation of FasL. Phosphorylation is not required for
ubiquitylation because FasL lacking all tyrosines
undergoes mono-ubiquitylation. These studies show that
phosphorylation and ubiquitin signals regulate the sorting
of FasL to secretory lysosomes by controlling entry into
multivesicular bodies.
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Results
The haemopoietic-specific Src-family tyrosine kinase,
Fgr, interacts with the PRD within the cytoplasmic tail of
FasL
Previous studies have shown that the PRD of FasL is required
for sorting to secretory lysosomes (Blott et al., 2001). We
therefore screened for proteins in haemopoietic cells able to bind
the PRD of FasL. The entire cytoplasmic tail of human FasL was
fused in frame with the Gal-4 DNA binding domain from yeast
and used to screen a human bone marrow derived cDNA library
in a yeast two hybrid assay. Approximately 1600 transformants
were screened and 200 positive clones were identified. 84 clones
were sequenced and analysed for PRD interacting domains. Four
SH3 domain-containing proteins were identified of, which the
most frequently isolated encoded Fgr, a Src-family tyrosine
kinase expressed in haemopoietic cells.
To verify biochemically that the SH3 domain of Fgr
interacted with the PRD of FasL a GST fusion protein
expressing the SH3 domain of Fgr was used to pull down
lysates from the rat mast cell line, RBL, expressing wild-type
(WT) or mutant FasL constructs, all fused to GFP (Fig. 1A).
Fig. 1B shows that the SH3 domain of Fgr is able to pull down
FasL only when the PRD is present. RBL cells do not express
endogenous FasL and no band is seen in the mock transfected
lane. GFP-tagged FasL (WT) expressed in RBL appears as a
band of 60 kDa when pulled down by the SH3 domain of Fgr
and probed with an antibody against FasL, but a deletion
mutant lacking the PRD (-Pro) is not pulled down. Our
previous studies revealed that mutation of KKR at the end of
the PRD (Fig. 1A) resulted in mis-sorting of FasL from the
lysosomes to the cell surface in RBL (Blott et al., 2001). We
therefore asked whether these lysines are critical for Fgr
binding. FasL-GFP in which the KKR motif was mutated to
the oppositely charged EEE motif was also able to bind the
SH3 domain of Fgr. Similarly, FasL in which all three tyrosines
(Y7, Y9, Y13), which form potential substrates for
phosphorylation, were mutated to alanines was able to bind the
SH3 domain of Fgr. In each case GST alone failed to pull down
FasL and western blotting of lysates was used to confirm
equivalent expression levels of all constructs. 
Journal of Cell Science 120 (1)
Fig. 1. Fgr binds FasL proline-rich
domain (PRD) residues 41-60.
(A) Amino acid sequences of the
cytoplasmic tails of WT, -Pro,
KKR and 3Y FasL. All constructs
are tagged with GFP at the amino
terminus and have wild-type
transmembrane and extracellular
domains at the carboxy-terminus.
Amino acid numbering is shown
with the PRD shaded and asterisks
marking the positions of tyrosine
and lysine residues. Amino acid
substitutions are underlined for each
construct and the deleted region in
-Pro is shown. Please note that
Figure 2a in a related paper (Blott et
al. 2001) contains a typographical
error, showing the sequence of C32
in FasL cytoplasmic tail as L. The
correct sequence is shown here (A),
and all constructs used in both
studies corresponded to this
sequence. (B) Western blots of pull
downs using Fgr-SH3-GST
incubated with cell lysates from
untransfected RBL (–) or RBL
expressing wild-type (WT) or mutant
FasL GFP-tagged constructs lacking
the PRD (-Pro), with K71, K72 and
R73 all mutated to glutamic acid
(KKR) or Y7, Y9, Y13 all mutated to
alanine (3Y). Controls of the total
lysate used in each pull down are
shown. All blots were probed with anti-FasL, G247-4. Molecular mass markers are shown ( kDa).
(C) Different concentrations [shown above peaks (M)] of monomeric Fgr-SH3 were passed over
a random peptide (solid line), peptide 1-20 (light dotted line) and peptide 61-80 (bold dotted line)
immobilised on a BIAcoreTM chip at 37°C. Protein injection points are indicated by horizontal
bars. (D) Different concentrations [shown above peaks (M)] of monomeric Fgr-SH3 were
passed over peptides corresponding to amino acids 1-20 (dotted line) and 41-60 (bold line)
immobilised on a BIAcoreTM chip at 37°C. Protein injection points are indicated by horizontal
bars. (E) Specific equilibrium binding values were plotted (squares) and the KD calculated by
nonlinear curve fitting (line) and Scatchard analysis (see inset graph).
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We mapped the binding site and affinity of the Fgr SH3
domain using surface plasmon resonance with 20 amino acid
peptides, spanning the cytoplasmic tail of FasL, bound to the
chip, and passing monomeric GST-SH3-Fgr across the bound
peptides. These studies showed binding only to peptide 41-60,
revealed by the difference in response units when Fgr-SH3 is
passed over peptide 41-60 compared with peptide 1-20 or an
irrelevant peptide (Fig. 1C) (Fig. 1C). Peptides corresponding
to 1-20 and 61-80 gave no binding above that of irrelevant
control peptides (Fig. 1D). Similarly, no binding above this
level was detected to peptide 21-40 (data not shown).
Measuring the response units of Fgr-SH3 binding to peptide
41-60 at varying protein concentrations (Fig. 1E) gave a
calculated affinity of 135 M. These results show that Fgr
binds to an SH3 binding motif contained within amino acids
41-60 with a relatively weak affinity.
The SH3 domains of Fyn, Lyn and Fgr but not Lck bind
to FasL
We then asked whether SH3 domains from other Src family
tyrosine kinases are also able to interact with FasL by using
SH3 domain fusion proteins derived from Lck, Fyn and Lyn.
GST alone does not pull down FasL-GFP expressed in RBL
cells. GST fusion proteins expressing the SH3 domains of Fyn,
Fgr and Lyn all pull down FasL-GFP (60 kDa) as well as a
degradation product of 40 kDa, however the SH3 domain of
Lck does not pull down FasL (Fig. 2). Protein expression levels
of all GST-SH3 domains were shown to be equivalent by
Coomassie blue staining (data not shown). These results show
that some but not all Src family tyrosine kinases can bind to
FasL. The finding that Lck could not bind FasL revealed that
although several of the kinases can bind, the interactions are
specific, confirming earlier peptide binding studies (Hane et
al., 1995).
RT-PCR was used to identify expression of related Src
family tyrosine kinases, Fgr, Fyn and Lyn in the NK-like cell
line, YT, and cells of a mixed lymphocyte reaction (MLR) of
human peripheral blood representing activated CD4 and CD8
T lymphocytes, all of which express endogenous FasL, as well
as in RBL cells, which do not express endogenous FasL. The
results demonstrate that tyrosine kinase expression varies
between cell types (Fig. 2B). The mast cell line RBL expresses
RNA encoding only Lyn and the NK cell line Fgr, Lyn and Lck.
RNA from the MLR express Fgr, Fyn and Lck. This shows that
cells that sort FasL to secretory lysosomes express a number
of tyrosine kinases capable of binding the PRD of FasL.
Over-expression of Fgr results in mis-localisation of
FasL to the early endosome
We asked whether Fgr might play a role in regulating sorting
of FasL to secretory lysosomes. When expressed after
transfection into RBL cells, FasL-GFP is targeted to the
lysosomes very efficiently and co-localises with the lysosomal
membrane marker, lgp120 (Fig. 3A) and not with the early
endosomal marker EEA1 (Fig. 3B). When Fgr-GFP is
expressed in RBL cells it localises both to the plasma membrane
and the early endosome but not to the lysosomes, partially co-
staining with EEA1 and not with lgp120 (Fig. 3C,D). When
FasL is co-expressed with Fgr, a pool of FasL co-localises with
the peri-nuclear pool of Fgr (Fig. 3E,F) partially overlapping
with EEA1 (Fig. 3F). We used the more sensitive and
quantitative technique of FACS analysis to ask whether there
was a change in cell surface levels of Fas ligand expression. Co-
expression of Fgr with FasL results in mis-localisation of FasL-
GFP to the plasma membrane relative to cells expressing equal
levels of FasL-GFP alone, as detected by FACS analysis using
the NOK-1 antibody, which recognises the extracellular domain
of FasL, to detect cell surface staining (Fig. 3G). By contrast,
over-expression of Fgr does not increase cell surface levels of
the lysosomal membrane protein, CD63 (Fig. 3H). Over-
expression of Lck, which does not bind FasL (Fig. 2), does not
result in mis-localisation of FasL to the plasma membrane
compared to cells expressing the same level of FasL-GFP (Fig.
3I). Lck is found only at the plasma membrane when expressed
in RBL (Fig. 3J), and does not co-localise with FasL (Fig. 3K).
These results suggest that Fgr specifically influences the sorting
of FasL to the lysosomes, with over-expression of Fgr
disrupting the lysosomal sorting of FasL and resulting in mis-
localisation of FasL to the plasma membrane.
Fas ligand is phosphorylated
FasL contains three potential sites of tyrosine phosphorylation
at residues Y7, Y9 and Y13. To determine whether FasL is
phosphorylated at these sites we mutated all three tyrosines to
alanines (3Y). Wild type, -Pro, KKR or 3Y FasL-GFP
chimeras were expressed in RBL. As previously reported, -
Pro and KKR were both mis-sorted with 21% and 25% of
protein appearing at the plasma membrane compared to 1.5%
of wild-type FasL on the plasma membrane while the rest is
targeted to the secretory lysosomes (Blott et al., 2001). The 3Y
Fig. 2. FasL interacts with members of the Src family of tyrosine
kinases. (A) GST alone or GST-fusion proteins of the SH3 domains
of Lyn, Lck, Fyn or Fgr were used to pull-down FasL from cells
lysates of RBL expressing FasL-GFP. The western blot was probed
with anti-FasL, G247-4. Molecular mass markers are shown (kDa)
and the arrow indicates the position of FasL-GFP. The 40 kDa band
is a degradation product. (B) Agarose gel separation of RT-PCR
products made with primers specific for rat Fgr, Fyn, Lyn and Lck
mRNA isolated from RBL, YT and a mixed lymphocyte reaction
(MLR) containing activated CD4+ and CD8+ T lymphocytes.
Products were verified by sequencing. DNA ladder markers are
shown on the left.
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mutation disrupts lysosomal sorting and 20% of
FasL appears on the plasma membrane (Fig. 4),
suggesting that the three tyrosine residues may also
be involved in lysosomal sorting. FasL was
immunoprecipitated using the anti-FasL antibody
NOK-1, and probed with either G247-4 anti-FasL,
or 4G10 anti-phosphotyrosine (Fig. 5A). Probing
immunoprecipitates with anti-FasL, reveals bands
of 60 kDa in WT, the KKR and 3Y mutants and a
band of 58 kDa for -Pro, but not in untransfected
RBL (–). Additional bands of 68 kDa are seen in
WT and 3Y immunoprecipitates, which may
correspond to a mono-ubiquitylated form of FasL.
Bands of 50 kDa corresponding to Ig heavy chain
from the immunoprecipitating antibodies are
present in all lanes. Probing the
immunoprecipitates with anti-phosphotyrosine
antibodies reveals bands corresponding to FasL for
WT, KKR and -Pro mutants, but the FasL band is
lacking in the 3Y mutant lacking all three tyrosines
even though equal amounts of protein are
immunoprecipitated in all samples. Additional,
albeit much fainter, bands of 66 kDa are visible in
immunoprecipitates from KKR and 3Y lysates with
an additional band of 58 kDa also visible for 3Y.
These bands are unlikely to correspond to FasL as
they are not recognised by anti-FasL when the filter
is stripped and re-probed. These bands may
represent other phosphorylated proteins associated
with FasL.
These results show that FasL is constitutively
phosphorylated in RBL cells even when the PRD
is absent. Since RBL express other tyrosine kinases
(Fig. 2) as well as a number of potential SH3-
domain binding sites in the first 40 amino acids of
the cytoplasmic tail, we examined FasL
phosphorylation in cells lacking expression of
haemopoietic tyrosine kinases.
Fgr binds to the PRD and phosphorylates
FasL
To determine whether Fgr, the tyrosine kinase
expressed endogenously in CTL and NK cells, is
able to phosphorylate FasL, we analysed the
phosphorylation state of FasL in HeLa cells. HeLa
Journal of Cell Science 120 (1)
Fig. 3. Overexpression of Fgr, but not Lck, leads to mis-
sorting of FasL. (A-F,J,K) Confocal images of
transiently transfected RBL expressing FasL-GFP
(A,B), Fgr-GFP (C-E), Fgr-YFP (F) and Lck-GFP
(J,K) or untagged FasL (E,K) and stained with
antibodies against Lgp120 (A,C), EEA1 (B,D,F,J) or
FasL (E,K). Scale bars represent 10 m (C,D,E,J,K) or
25 m (A,B,F). (G-I) FACS plots showing cell surface
expression of FasL (G,I) or CD63 in RBL expressing
equal levels of FasL-GFP or CD63-GFP. Surface
staining was measured using antibodies against the
extracellular domains of FasL, or CD63 in the presence
of the metalloprotease inhibitor BB3013. RBL
expressing FasL-GFP alone are shown as red histograms
and RBL expressing FasL-GFP and either Fgr (G,H) or
Lck (J) are shown as blue histograms.
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cells express endogenous Src (Black, 1992), but lack
expression of the haemopoietic-restricted Src family tyrosine
kinases Fgr, Fyn and Lyn. FasL-GFP expressed in HeLa is not
phosphorylated unless co-expressed with Fgr, when bands of
60 kDa, corresponding to FasL-GFP and 70 kDa,
corresponding to autophosphorylated Fgr-YFP are seen (Fig.
5B). FasL -Pro is not phosphorylated in HeLa cells and the
58 kDa -Pro-GFP is absent in the anti-phosphotyrosine blot,
regardless of Fgr co-expression. A faint, non-specific band of
64 kDa, is visible in WT and -Pro lanes, but does not appear
when re-probed with anti-FasL. These results show that FasL
is phosphorylated by Fgr when the PRD, where Fgr binds FasL,
is present.
FasL is mono-ubiquitylated
Studies on the EGFR have revealed phosphorylation is a pre-
requisite for mono-ubiquitylation and internalisation into
MVBs by the ESCRT-mediated pathway (Sorkin et al., 1992).
Our previous studies showed that positively charged arginine
and lysine residues at the ends of the poly-proline region in the
cytoplasmic tail of FasL were likely to play an important part
in SH3-mediated binding to the PRD and for this reason these
positively charged residues were also deleted in the -Pro
mutant (Fig. 4). This mutant therefore also lacks the only
potential sites of ubiquitylation in the cytoplasmic tail of FasL.
Hence we asked whether K72 and K73 in FasL might also
undergo ubiquitylation and, if so, whether phosphorylation is
a pre-requistie for mono-ubiquitylation of FasL
FasL was immunoprecipitated using NOK-1 (Fig. 6A).
Lysates and one tenth of the total immunoprecipitate were
probed with anti-FasL, while the remainder of the
immunoprecipitate was probed with the anti-ubiquitin
antibody, P4D1. Cell lysates from FasL-GFP and FasL-KKR
transfected cells, in which both potential sites of mono-
ubiquitylation K72 and K73 as well as R74 have been changed
to glutamic acid, were compared. In lysates, WT and 3Y reveal
strong bands at 60 kDa and a weaker band at 68 kDa, whereas
the KKR mutant shows only bands at 60 kDa and the -Pro at
58 kDa, consistent with the deletion of the PRD.
Immunoprecipitation of FasL followed by immunoblotting
with P4D1 reveals that the 68 kDa band corresponds to mono-
ubiquitylated FasL and is present only in WT and 3Y mutants.
This was confirmed by re-probing the filters with the G247-4
anti-FasL antibody. This shows that FasL is ubiquitylated, and
ubiquitylation is abolished by deletion of the only two lysines,
K72 and K73, in the cytoplasmic tail of FasL, both in the KKR
and -Pro mutants. Phosphorylation, however, is not a pre-
requisite of ubiquitylation since the 3Y mutant, which lacks all
tyrosine residues in the cytoplasmic tail, is ubiquitylated.
Mutations affecting phosphorylation and ubiquitylation
prevent FasL internalisation into MVBs
Over-expression of Fgr resulted in perinuclear retention of
FasL in RBL, partially overlapping with Fgr and EEA1,
Construct  Cell surface expression Reference 
Wild-type  1.5%     Blott et al., 2001 
-Pro   25%    Blott et al., 2001
KKR   21%    Blott et al., 2001
3Y   20%    Present study (see B) 
B
Fig. 4. Cell surface expression of FasL mutants in RBL cells. 
(A) Cell surface expression of Fas ligand as a percentage of total
FasL expression in cells expressing equal levels of GFP (protein).
(B) FACS plot showing histograms of cell surface expression of FasL
in RBL transiently transfected with WT (shaded) and 3Y (unshaded)
FasL-GFP constructs, gated for equal expression of GFP and stained
with the NOK-1 antibody against the extracellular domain of FasL,
in the presence of metalloprotease inhibitor BB3013.
Fig. 5. FasL is phosphorylated by Fgr
binding to the PRD. (A) Western blots
of lysates from stably transfected RBL
clones expressing equivalent levels of
FasL-GFP (WT) and the GFP-tagged
FasL mutants (KKR, -Pro and 3Y),
immunoprecipitated (IP) with anti-
FasL antibody MIKE 1 and Protein-G-
Sepharose or Protein-G-Sepharose
alone (–). The blot was probed with
anti-phosphotyrosine (PY) antibody
4G10 (upper panel) and stripped and
re-probed with anti-FasL antibody
G247-4 (lower panel). Arrows denote
the positions of bands corresponding
to phosphorylated FasL-GFP (P-FasL-
GFP), FasL-GFP and the -Pro mutant as well as IgG heavy chain (IgGHc). (B) Immunotyrosine blot of HeLa cells expressing untagged WT
and -Pro FasL and Fgr-YFP (+) as indicated probed with anti-phosphotyrosine (PY) antibody 4G10 (upper panel) and stripped and re-
probed with anti-FasL antibody G247-4 (lower panel). Arrows denote the positions of bands corresponding to phosphorylated Fgr (P-Fgr-YFP),
FasL-GFP (P-FasL-GFP), FasL-GFP and the -Pro mutant. Positions of molecular masses are shown (kDa).
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supporting the idea that a critical sorting step affected by
phosphorylation may occur in an endosomal compartment with
these markers. ESCRT mediated sorting into MVBs occurs in
the early or sorting endosomes. Studies on the EGFR, the
tyrosine receptor kinase, have shown that a kinase dead mutant
K721A fails to undergo internalisation into MVBs (Felder et
al., 1990). In addition, tyrosine auto-phosphorylation of EGFR
is required for its mono-ubiquitylation (Waterman et al., 2002).
We therefore examined mutations in FasL that prevented
phosphorylation and ubiquitylation for their ability to
internalise FasL into MVBs.
FasL localisation in MVBs of RBL was determined using
immunogold labelling against the extracellular domain of FasL
using the antibody NOK-1 (Fig. 7A). The number of gold
particles per MVB was counted. MVBs were classified as
vesicles of 200-600 nm diameter encompassing multivesicular
structures. Only MVBs bearing gold particles were included in
the calculations. In RBL expressing wild-type FasL-GFP, 43%
of MVBs contained 1-10 gold particles with another 38%
containing 11-20 gold particles per MVB and the remaining
19% more than 20 gold particles per MVB (Fig. 7B). By
contrast, in RBL expressing -Pro, 97% of MVBs contained
1-10 gold particles per MVB and only a single MVB was
observed containing 13 gold particles. RBL expressing the
KKR mutant of FasL showed 90% of MVBs containing 1-10
gold particles per MVB and only 10% with 11-20 gold
particles. Similarly in RBL expressing the 3Y mutant, 89% of
MVBs contained 1-10 gold particles and only 11% contained
11-20 gold particles. These results suggest that although wild-
type FasL-GFP is readily internalised into MVBs, disruption
of either phosphorylation or ubiquitylation motifs disrupts this
sorting step.
Discussion
The packaging of FasL into small vesicles within secretory
lysosomes (Andreola et al., 2002; Frangsmyr et al., 2005;
Smith et al., 2003) is important for the delivery of active FasL
at the immunological synapse. FasL, which is transferred to the
plasma membrane is rapidly inactivated by a cell surface
metalloprotease that cleaves off the extracellular domain of
FasL, producing a soluble form of FasL, which is 1000 times
less active than transmembrane FasL (Kayagaki et al., 1995;
Mariani et al., 1995). The delivery of small vesicles into the
immunological synapse allows FasL to avoid the
metalloprotease and remain in the membrane-bound form,
which is efficient at cross-linking Fas on the target membrane.
Previous studies revealed that FasL is packaged in secretory
lysosomes in haemopoietic cells whereas in other cell types,
such as epithelial cells, FasL is expressed at high levels on the
plasma membrane (Blott et al., 2001). The targeting motif for
secretory lysosome localisation was identified as a proline-rich
region of the cytoplasmic tail of FasL and deletion of this 20
amino acid stretch results in cell surface expression of FasL in
haemopoietic cells. These results suggested that the proline-
rich domain of FasL might provide a cell-type-specific sorting
motif for secretory lysosome localisation in haemopoietic cells.
Using a yeast two hybrid approach we identified interactions
between the haemopoietic-specific Src family tyrosine kinase,
Fgr. Expression of Fgr is restricted to haemopoietic cells of the
myeloid lineage including monocytes, macrophages and
neutrophils (Thomas and Brugge, 1997; Willman et al., 1987),
as well as natural killer cells (Biondi et al., 1991) and some B
cell subsets (Link and Zutter, 1995). The activation of Src
family tyrosine kinases is regulated by the balance between
dephosphorylation and phosphorylation (Sicheri and Kuriyan,
1997; Young et al., 2001), which would result from the cascade
of signalling events that accompany receptor antigen
recognition by both T cells and NK cells. FasL transcription
and biosynthesis are both upregulated by T-cell receptor (TcR)
recognition (Vignaux et al., 1995) and new synthesis of FasL
will therefore coincide with Fgr activation.
In this paper we show that both phosphorylation and mono-
ubiquitylation signals are required for efficient lysosomal
targeting of FasL via the MVB pathway. We show that Fgr
binding to the PRD (amino acids 43-74) is required for efficient
phosphorylation of FasL in HeLa cells, which lack endogenous
expression of the haemopoeitic Src family tyrosine kinases. In
RBL cells, which do not express Fgr or Fyn, but do express
Lyn and possibly other related kinases, we identify a critical
role for phosphorylation by deletion of tyrosine residues Y7,
Y9 and Y13 that reduce the efficiency of FasL entry into
MVBs. In addition we find that FasL is mono-ubiquitylated
and deletion of the two possible lysine substrates at amino
acids 72 and 73 prevents ubiquitylation and also impairs entry
of FasL into MVBs. Unlike the EGFR, where phosphorylation
is a prerequisite to ubiquitylation, FasL ubiquitylation is not
dependent on phosphorylation, as the 3Y mutant is still
efficiently ubiquitylated. Conversely phosphorylation is not
dependent on mono-ubiquitylation, as FasL lacking lysines is
efficiently phosphorylated (Fig. 5). These results suggest that
both phosphorylation and mono-ubiquitylation contribute to
sorting FasL independently. In T cells, which express
endogenous FasL and Fgr, the PRD will therefore contribute
both to phosphorylation and mono-ubiquitylation, serving as a
Journal of Cell Science 120 (1)
Fig. 6. FasL is monoubiquitylated in vivo.
Western blots of cell lysates from stable
transfectants of RBL expressing equivalent
levels of WT or FasL-GFP mutants (KKR, -
Pro and 3Y) or 1/10 of the immunoprecipitates
both probed with anti-FasL, G247-4 and 9/10
of the same immunoprecipitate probed with
anti-Ub, P4D1. Arrows denote the position of
bands corresponding to ubiquitylated FasL
(Ub-FasL-GFP) and IgG heavy chain (IgGHc).
Note that both KKR and -Pro constructs lack
K72 and K73 (Fig. 1). Positions of molecular
masses are shown (kDa).
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binding site for Fgr, which can phosphorylate FasL, and with
K72 and K73 providing the substrate sites for mono-
ubiquitylation.
Our data indicate that both phosphorylation and
ubiquitylation are necessary for the appearance of FasL within
the MVBs. We do not know whether phosphorylation and
mono-ubiquitylation occur at different steps along the
endocytic/secretory pathway. However detection of cell surface
FasL requires the use of metalloprotease inhibitors (Blott et al.,
2001; Bossi and Griffiths, 1999), consistent with literature
detailing the cleavage of the extracellular
domain (recognised by antibodies) by cell
surface metalloproteases (Tanaka et al., 1998).
This suggests that FasL reaches secretory
lysosomes directly via the biosynthetic
pathway and that both phosphorylation and
ubiquitylation are likely to play a role in the
biosynthetic sorting of FasL.
We find that a number of the haemopoietic-
restricted tyrosine kinases are able to bind
FasL and this might explain how FasL is
successfully sorted to the secretory lysosomes
of a number of haemopoietic cells. Although
RBL do not express Fgr, this cell line does
express a number of other tyrosine kinases,
including Lyn. Our finding that FasL is
constitutively phosphorylated in RBL, even
when lacking the PRD, suggests that other
tyrosine kinases expressed in RBL can bind
outside the PRD and lead to phosphorylation.
It should be noted that FasL -Pro lacks K72
and K73, and therefore cannot be mono-
ubiquitylated and consequently is mis-sorted
to the plasma membrane in RBL. Since we
were unable to knock down gene expression
in RBL cells we were unable to address the
role of other tyrosine kinases in FasL sorting
in RBL. Interestingly, in HeLa cells in which
FasL localises predominantly to the plasma
membrane, co-expression with Fgr reduces
the cell surface localisation of FasL by
approximately one third (data not shown).
Our results demonstrate that
phosphorylation of FasL varies in different
cell types, dependent upon the tyrosine
kinases expressed. The finding that FasL
binds some, but not all, of the haemopoietic-
specific Src family tyrosine kinases provides
a potential mechanism for the lineage specific
sorting of FasL in cells with secretory lysosomes. In HeLa
cells, which express Src but lack the haemopoeitic-specific
tyrosine kinases, FasL is only phosphorylated when co-
expressed with Fgr.
Taken together the findings presented here suggest that
FasL sorting to secretory lysosomes is regulated in at least two
ways by the PRD. Fgr binding to the PRD leads to
phosphorylation of FasL and in addition a KKR motif at one
end of the PRD forms the site of a mono-ubiquitylation
modification. Our data show that both phosphorylation and
Fig. 7. Phosphorylation and ubiquitylation
modifications are required for FasL sorting into
MVBs. (A) Immunogold labelling of cryo-sections
from stable transfectants of RBL expressing
equivalent levels of WT, -Pro, KKR and 3Y
GFP-tagged constructs of FasL, detected with
NOK-1 labelling of the extracellular domain of
FasL and Protein A-gold. Bars, 100 nm. (B)
Quantification of number of gold particles in
MVBs when WT, -Pro, KKR and 3Y FasL are
expressed in RBL. Equivalent expression levels of
FasL were confirmed by western blotting.
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ubiquitylation control internalisation into the inner vesicles of
MVBs independently. FasL sorting into MVBs is important
for localisation into exosome-like vesicles that are released
into the immunological synapse and provide optimally active
membrane-bound FasL able to cleave Fas on target cells and
trigger rapid cell death.
Materials and methods
Antibodies and cell lines
The antibodies used were: mouse anti-human FasL NOK-1 (Pharmingen), rat anti-
human FasL MIKE1 (Apotech), mouse anti-human FasL G247-4 (mouse IgG1;
PharMingen), mouse anti-human CD63, H5C6 (Developmental Studies Hybridoma
Bank, Iowa), mouse anti-Phosphotyrosine 4G10 (Upstate), mouse anti-ubiquitin
P4D1 (Santa Cruz Biotechnology), HRP-conjugated anti-phosphotyrosine RC20H
(Transduction Laboratory), rabbit anti-rat Lgp 120 (Mark Marsh, UCL), mouse anti-
EEA1 (Becton Dickinson), mouse anti-human Lck (Becton Dickinson), rabbit anti-
Fgr (Santa Cruz Biotechnology), mouse anti-myc antibody (Covance), anti-GFP BD
Living ColorsTM A.v. peptide antibody (BD Bioscience), HRP-conjugated anti-
mouse secondary antibody (Jackson Immunoresearch). RBL (rat basophilic
leukemia), human HeLa and Jurkat cell lines were grown in DMEM medium
(Gibco) supplemented with 10% foetal calf serum (FCS).
Plasmid constructs
Constructs were generated either by PCR or by direct subcloning. Wild type (WT),
Pro-GFP and KKR FasL-GFP chimeras were constructed as previously described
(Blott et al., 2001; Bossi and Griffiths, 1999; Bossi et al., 2000). 3Y was generated
by Quick ChangeTM Site Directed Mutagenesis kit (Stratagene) using WT FasL-
GFP as a template. Full-length human Lck was a kind gift from M. Marsh (UCL,
London) and full-length human Fgr and Lyn were amplified by RT-PCR. Fgr-GFP,
Lck-GFP and Fgr-YFP were constructed by cloning full-length human sequences
into pEGFP-N3 or pEYFP-N3 (Clontech) amplified by PCR using the following
primers: Fgr-5 primer 5- CGGGAATTCGTTATGGGCTGTGTGTTCTGC-3,
Fgr-3 primer 5-CCGGACGGTACCAACTGTCTGATCCCCGGG-3; Lck-5
primer 5-CGGGAATTCGTTATGGGCTGTGGCTGCAGC-3, Lck-3 primer 5-
CCGGACGGTACCAACAGGCTGAGGCTGGTA-3; Lyn-5 primer 5-CGGG -
AATTCGTTATGGGATGTATAAAATCA-3, Lyn-3 primer 5-CCGGACGGTAC-
CAACAGGCTGCTGCTGGTA-3. pGEX-2T-Fgr-SH3 was a kind gift from I.
Gout. Lyn-SH3 was subcloned into pGEX-2T (Amersham Biosciences) using the
primers: 5-primer 5-CGGACCGGATCCCAAGGAGACATTGTG-3, 3-primer
5-GGACCGGAATTCTCAGGTGTTGAGTTT-3, which encode a BamHI and
EcoRI restriction site, respectively. Fyn-SH3 and Lck-SH3 were gifts from M.
Brown.
Reverse transcriptase PCR (RT-PCR)
Full-length human Fgr and Lyn were amplified by RT-PCR from mixed lymphocyte
reaction (MLR) and YT RNA, respectively, using the following primers; Fgr 5
primer 5-GGGAACCTGGAAATGGGCTGTGTGTTCTG-3, Fgr 3 primer 5-
TGCCCGGACAGGCTATGTCTGATCCCCGG-3; Lyn 5 primer 5-TCACGC-
GAGCGGGAAATATGGGATGTAT-3, Lyn 3 primer 5-GGTCTCCCTGTGCTC-
TAAGGCTGCTGCT-3. RNA from various cell lines were screened for the
expression of Fgr using the following species specific primers; human 5 primer 5-
GTGTGTCAGGGATTGGGGTGACCCTGT-3; human 3 primer 5-CACAGCC-
CGTCATTCACCTCCATGTAG-3; murine 5 primer 5-GCATCTCAGGGACCG-
GAGTGACCATAT-3; murine 3 primer 5-CACAGACCATCATTCACTTCCAT-
GTAG-3; rat 5 primer 5-GCGTCTCTGGGACGGGAGTGACCATAT-3; rat 3
primer 5-CATAGACCGTCATTCACTTCCATGTAG-3. These primers were
designed across intron-exon boundaries. RBL RNA was screened for the presence of
various tyrosine kinases using the following primers; Fyn 5 primer 5-GTCACG-
GAATACATGAACAAAGGAA-3; Fyn 3 primer 3 5-GGAAACTTTGCAC-
CTTGTCTGGCTGT-3; Lck 5 primer 5-TAGGCAGGGGACTTGTACTGA-
GAAG-3; Lck 3 primer 5-TCACAGGAGGCTCAGGCCAAGGCTGG-3; Lyn
5 primer 5-ATTACCGAGTTCATGGCCAAGGGTA-3; Lyn 3 primer 5-TCA -
CAGGAGGCTCAGGCCAAGGCTGG-3. These primers were designed to prime
across areas that are divergent among the family members.
Transfection
5106 RBL cells were transfected using AMAXA Nucleofactor System according
to the manufacturer’s instructions. 8105 HeLa cells were transfected using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Transient transfectants were analysed 24 hours post-transfection. To obtain stable
transfectants, RBL cells were transfected by electroporation at 500 F and 250 mV
(Biorad, Richmond, California) and selected by supplementing the growth medium
with 1 mg ml–1 G418 (Gibco) 24 hours post-transfection.
Cell lysates
Cells were lysed in lysis buffer (50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, 2%
NP40 containing 1 Complete Protease Inhibitor (Roche), 10 mM NEM (Sigma),
1 mM Phosphatase Inhibitor Cocktail 2 (Sigma) at 4107 cells ml–1, incubated on
ice 20 minutes and centrifuged for 10 minutes at 13000 g to pellet debris.
GST-pull down assay
Lysates were pre-cleared with 15 l GST-Sepharose beads (Pharmacia) 1 hour at
4°C and incubated over night at 4°C with GST fusion proteins immobilised onto
GST-Sepharose. The samples were then washed with lysis buffer and 0.1% Triton
X100, eluted with Gluthatione elution buffer (10 mM Gluthatione in 50 mM Tris-
HCl) for 20 minutes at room temperature. Samples were separated by SDS-PAGE
transferred to nitrocellulose and probed with anti-FasL antibody, G247-4. A small
fraction of the eluate was also analysed by SDS-PAGE and stained with Coomassie
blue to demonstrate equal amounts of GST fusion protein were used in each sample
(data not shown).
Immunoprecipitation
Cell lysates were pre-cleared with 15 l Protein-G Sepharose (Pharmacia Biotech)
for 1 hour at 4°C, incubated over night at 4°C with 40 l Protein-G Sepharose that
had been pre-incubated with 1.5 l of anti-FasL Mike 1 antibody (Apotech).
Immunoprecipitates were washed three times with Assay Buffer (25 mM Hepes pH
7.2, 125 mM KAc, 2.5 mM MgAc, 5 mM EGTA, 1 mM DTT) supplemented with
the 1 mM Phosphatase Inhibitor Cocktail 2 (SIGMA). Samples were separated by
SDS-PAGE and analysed by immunoblotting. The blot was probed with anti-
Phosphotyrosine 4G10 antibody (Upstate).
Western blotting
Samples from GST-pull down, immunoprecipitation experiments or cell lysates,
were eluted in NuPage Sample Buffer containing Reducing Agent (Invitrogen) and
separated by SDS-PAGE using NuPage Novex 4-12% Bis-Tris gel in the XCell
SureLock System with MOPS SDS Running Buffer (Invitrogen). Following SDS-
PAGE, the proteins were transferred to an Invitrolon-PVDF (Invitrogen) membrane
and blocked in 5%milk/PBS-0.2% Tween 20 (Sigma), incubated with the designated
antibody and a horseradish peroxidase (HRP)-conjugated anti mouse secondary
antibody (Jackson) before detection with a Super-Signal chemioluminescence kit
(Pierce). When 4G10 antibody was used, the membrane was blocked in
5%BSA/TBS-0.1% Tween20 and the primary antibody was diluted in
3%BSA/TBS-0.1% Tween20.
Ubiquitylation assay
For the in vivo ubiquitylation assay, RBL cells were lysed in JS buffer (50 mM
HEPES PH 7.5, 50 mM NaCl, 1% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 5
mM EGTA) plus protease and phosphatase inhibitors (20 mM Na pyrophosphate
pH 7.5, 25 g ml–1 aproteinin, 25 g ml–1 leupeptin, 50 mM NaF, 2 mM PMSF,
0.5 M Na vanadate in HEPES pH 7.5). 4 mg of lysates were subjected to
immunoprecipitation with mouse monoclonal antibody against human FASL (NOK-
1, BD Pharmingen) and protein G (Zymed). Immunoprecipitates were washed in
RIPA buffer (50 mM Tris, 150 mM NaCl, 1% triton, 1% deoxycholate, 0,1% SDS)
plus protease and phosphatase inhibitors as before. Anti-ubiquitin immunoblot was
performed using P4D1 monoclonal antibody (Santa Cruz Biotechnology) as
described previously (Avantaggiati et al., 1996). Anti-FasL immunoblots were
performed using G247-4 mouse monoclonal antibody (BD Pharmingen).
Immunostaining, confocal microscopy and FACS analysis
Immunostaining and confocal microscopy have been previously described (Blott
et al., 2001). For EEA1 staining cells were fixed in 2% PFA for 15 minutes at
room temperature. All images were acquired sequentially to prevent ‘bleed-
through’ between channels. FACS analysis was as described (Blott et al., 2001).
RBL FasL-GFP and CD63-GFP transfectants were plated in six-well dishes 12
hours prior to FACS staining. 2 hours prior to FACS staining, the cell medium
was supplemented with 10 M BB3013 metalloprotease inhibitor (British
Biotech, Oxford), after, which the dishes were placed on ice for 10 minutes. The
medium was replaced with 1 g ml–1 NOK-1, anti-CD63 antibody or relevant
control antibody, diluted in medium plus 10 M BB3013, and incubated for 30
minutes on ice. The cells were washed with FACS buffer (1%FCS/ PBS with 1
M sodium azide), then fixed with 1% paraformaldehyde (Electron Microscopy
Sciences, Washington, USA) in FACS buffer for 15 minutes at room temperature.
The cells were washed further, and then incubated for 30 minutes with PE-
conjugated goat anti-mouse secondary antibody (final concentration 50 g ml–1
in FACS buffer; Jackson Immunoresearch, West Grove, Pennsylvania, USA). The
cells were washed three times in FACS buffer, and then scraped from the dishes
into FACS tubes, and re-suspended in a final volume of 1 ml FACS buffer. The
samples were analysed using a FACScalibur flow cytometer (Becton Dickinson).
PE fluorescence was measured at 575 nm and GFP fluorescence at 525 nm.
Fluorescence data was collected for 30,000 events on a four orders of magnitude
log scale and analysed using CELLQuest (Becton Dickinson) software. Cells
analysed for surface FasL or CD63 expression were gated so that all expressed
equal levels of GFP. Cell surface expression is shown as a percentage of total FasL
expression, determined by the amount of GFP.
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Electron microscopy
Cells were fixed in 4% (~10 minutes) followed by 8% paraformaldehyde in 250
mM HEPES buffer (pH 7.4) for 2 hours. The cells were washed in 250 mM HEPES
buffer containing 50 mM glycine for 1 hour at room temperature to quench free
aldehydes and released from the plastic by scraping. Cells were pelleted in 3%
gelatin, cryo-protected with 2.3 M sucrose, and cryosectioned using a Reichert
Ultracut E with the FCS attachment. Cryosections of 65 nm nominal thickness were
collected onto formvar-coated nickel grids using a 1:1 mixture of 2.3 M sucrose and
2% methylcellulose (Liou et al., 1996) and immunolabelled with NOK-1 (1:20
dilution) followed by goat anti-mouse IgG conjugated to 10 nm gold (British
Biocell, UK). Sections were examined in either a Tecnai 12 (FEI, Eindhoven, The
Netherlands) or a Zeiss Omega 912 electron microscope (Zeiss SMT, Oberkochen,
Germany) equipped with a Proscan cooled slow-scan charge-coupled device camera
(20482048 pixels). For quantification, digital images were analysed using
EasiVision SIS image analysis software (Soft Imaging Software, Münster,
Germany).
BIAcore analysis
Recombinant Fgr-SH3 GST was prepared and then further purified by gel filtration
using Superdex 75 (Amersham Biosciences). Monomeric fractions were used on the
same day. Experiments were carried out on a BIAcore 2000 (BIAcore AB), at 37°C,
using HBS buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA and
0.005% surfactant P20) supplied by the manufacturer. Biotinylated peptides (Sigma-
Genosys) were captured by streptavidin immobilised on a research grade CM5 chip.
The sequence of the irrelevant peptide control, with no known SH3-binding motifs
was PDNSSDSD(pTyr)DLHGAQRL. 10 l SH3 protein was injected at 20 l
minute–1 over the peptides, at decreasing concentrations. Affinity data were
analysed using the software SigmaPlot. Similar Kd values were obtained by non-
linear fitting of the simple single site saturation binding equation to the BIAcore
data, and by liner curve fitting of the Scatchard plot.
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